Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG002 in HER2-positive unresectable or metastatic biliary adenocarcinoma
CTR20210312Phase 2Terminated
- Sponsor
- Hangzhou Miracogen
- Start
- Feb 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MRG002 in biliary adenocarcinoma, sponsored by Hangzhou Miracogen. Started Feb 2021; status: terminated.
02
Drugs
MRG002
03
Conditions
biliary adenocarcinoma
Beyond the preview
Go deeper on CTR20210312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210312.